Tag: KTE-X19

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

byNeel Mistryand1 others

August 17, 2021

1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

#VisualAbstract: Reduced-Dose was Not Non-Inferior to Full-Dose Direct Oral Anticoagulants in Venous Thromboembolism Patients
2 Minute Medicine Rewind March 10, 2025
CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

No Result

View All Result